The bulk of evidence for proposing these criteria comes from results from CSF amyloid and tau biomarkers in patients with LOEU and from studies of cognitively intact individuals without epilepsy who demonstrate positive biomarkers. This evidence concerns the gene MAPT and epilepsy.